Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

AVIR Sales of Investments

Cash received from selling or redeeming investments.

Atea Pharmaceuticals, Inc.NASDAQ: AVIR

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $104.28M fell 49.9% year over year, behind the -26.9% change in trailing-twelve-month sales of investments. Sequentially, it rose 15.4% from the prior quarter. Over 3 fiscal years it compounded at +72.4% a year.

Context

  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -49.9% toward the trailing-twelve-month pace of -26.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$104.28M+15.4% QoQ
Last fiscal yearDec 2025
$470.73M-9.0% YoY
LTMMar 2026
$366.77M-26.9% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.9%——
1 year-9.0%——
3-year CAGR+72.4%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
470.73M USD
Year-over-year change
-9.0%

Sales of Investments vs competitors

How AVIR compares with its peers on the latest reported figures

  • AVIR's LTM Mar 2026 sales of investments of $366.77M is the 2nd largest of the 5 companies compared; the peer median is $217.51M.
  • Its year-over-year change of -26.9% is the 4th highest of 5, against a peer median of -8.8%.
  • Over three fiscal years its annual growth of +72.4% compares with a peer median of +22.6%.
AVIR Competitors Peer median
Sales of Investments for AVIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$1.07B -26.1%+50.6%1633.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$366.77M -26.9%+72.4%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$287.42M +13.1%+4.8%415.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$147.6M +8.4%-0.1%207.6%
ABUSArbutus Biopharma CorporationLTM Mar 2026$125.21M -27.8%+40.5%65.4%
Peer median (excluding AVIR) $217.51M-8.8%+22.6%311.4%

Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income121.19M(115.91M)(135.96M)(168.39M)(158.35M)
Depreciation & Amortization29K260K416K416K416K
Deferred Income Tax(29.39M)0(48.56M)0(6.36M)
Stock-Based Compensation39.62M46.72M49.43M51.77M20.72M
Change in Working Capital(247.85M)(46.59M)16.16M(7.48M)16.48M
Accounts Receivables00000
Inventory00000
Accounts Payables10.29M(1.98M)1.7M206K8.49M
Other Working Capital(258.13M)(44.6M)14.46M(7.68M)8M
Other Non-Cash Items29.39M(5.47M)33.11M(11.82M)(4.94M)
Operating Cash Flow(87.01M)(120.98M)(85.4M)(135.5M)(132.03M)
Capital Expenditures(4K)(1.94M)000
Acquisitions (Net)0453.47K000
Purchases of Investments0(545.35M)(562.36M)(461.18M)(281.94M)
Sales of Investments091.89M602.67M517.28M470.73M
Other Investing Activities0(453.47K)000
Investing Cash Flow(4K)(455.41M)40.3M56.11M188.79M
Debt Repayment00000
Common Stock Issued1.47M230K257K267K259K
Common Stock Repurchased0000(25.52M)
Dividends Paid00000
Other Financing Activities0140K00(485K)
Financing Cash Flow1.47M370K257K267K(25.75M)
Effect of Forex Changes00000
Net Change in Cash(85.54M)(576.02M)(44.84M)(79.13M)31.02M
Free Cash Flow(87.01M)(122.93M)(85.4M)(135.5M)(132.03M)

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.